Jereme M. Sylvain - Jun 10, 2024 Form 4 Insider Report for DEXCOM INC (DXCM)

Role: EVP Chief Financial Officer
Signature: Jereme M Sylvain
Stock symbol: DXCM
Transactions as of: Jun 10, 2024
Transactions value $: -$85,713
Form type: 4
Date filed: 6/11/2024, 06:39 PM
Previous filing: Mar 14, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DXCM	Common Stock	Sale	-$85.7K	-745	-0.87%	$115.05	84.9K	Jun 10, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2	Included in this number are 50,549 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,924 of which were granted on December 15, 2021 and shall vest through December 15, 2024 and 159 additional shares purchased pursuant to the DexCom, Inc. 2015 Employee Stock Purchase Plan.

Content

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Included in this number are 50,549 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,924 of which were granted on December 15, 2021 and shall vest through December 15, 2024 and 159 additional shares purchased pursuant to the DexCom, Inc. 2015 Employee Stock Purchase Plan.